APR 16, 2019 8:33 AM PDT

FDA Approves New Osteoporosis Drug for Post-Menopausal Women

WRITTEN BY: Tiffany Dazet

The U.S. Food and Drug Administration recently approved a new treatment to combat osteoporosis in high-risk postmenopausal women. Osteoporosis is a disease that weakens bones, making them more susceptible to breaks. The National Osteoporosis Foundation estimates that 50% of women and 25% of men will break a bone in their lifetime due to osteoporosis. In the FDA’s release about the new drug Elizabeth Thompson, the CEO of the National Osteoporosis Foundation, estimated that “80 percent of patients who have had one or more osteoporotic-related fractures are not being identified or treated." 

For women, osteoporosis is a higher risk than heart attack, stroke, and breast cancer combined. Post-menopausal women are at a higher risk for osteoporosis due to reductions in estrogen production, which among other things helps to protect bone density. The Office on Women’s Health estimates that women may lose up to 25% of bone mass in the first ten years after menopause. 

The drug—romosozumab, branded as Evenity—was co-developed by biopharmaceutical companies Amgen and UCB, based in the United States and Belgium, respectively. Evenity is a bone-building treatment that will both increase bone formation and reduce bone loss to reduce the risk of fracture. Technically speaking, it is a bone-building humanized monoclonal antibody that works by inhibiting the activity of sclerostin to achieve the desired results. Development of Evenity included 19 clinical studies with more than 14,000 patients since 2004, two of which focused solely on post-menopausal women. 

In the FDA’s announcement the executive vice president of Research and Development at Amgen, Dr. David Reese stated that “the FDA approval of Evenity represents an important therapeutic development for patients who need a medicine that can rapidly increase bone mineral density and reduce the risk of future fractures within 12 months.”

Side effects of Evenity include the increased risk of heart attack, stroke, and cardiovascular death. Because of these risks, Amgen officials caution that patients should be selected very carefully to ensure that the benefits of the drug outweigh the risks. 

The treatment must be administered by a healthcare professional and consists of 12 injections. If further osteoporosis treatment is necessary after 12 months, a different type of treatment should be used. Evenity is expected to be available in the United States this month.

Sources: FDA, CNN, Office of Women's Health, National Osteoporosis Foundation
 

About the Author
  • Tiffany grew up in Southern California, where she attended San Diego State University. She graduated with a degree in Biology with a marine emphasis, thanks to her love of the ocean and wildlife. With 13 years of science writing under her belt, she now works as a freelance writer in the Pacific Northwest.
You May Also Like
SEP 02, 2021
Immunology
Hobit Activates Cancer-Killing Immune Cells
SEP 02, 2021
Hobit Activates Cancer-Killing Immune Cells
Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. Thes ...
SEP 08, 2021
Microbiology
Authorities Work to Contain Nipah Virus Outbreak in India
SEP 08, 2021
Authorities Work to Contain Nipah Virus Outbreak in India
Nipah virus is one of the world's deadliest viruses. It has caused several small outbreaks in Southeast Asia since it em ...
SEP 14, 2021
Immunology
Extinguishing Fires in the Brains of MS Patients
SEP 14, 2021
Extinguishing Fires in the Brains of MS Patients
  A closer look at the brains of patients with aggressive, debilitating forms of multiple sclerosis (MS) reveals so ...
SEP 14, 2021
Health & Medicine
This is your brain on doom: Steven Pinker's New Book on Rational and Irrational Societies
SEP 14, 2021
This is your brain on doom: Steven Pinker's New Book on Rational and Irrational Societies
In his new book, cognitive psychologist and linguist, Steven Pinker, argues for more rational societies
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
SEP 22, 2021
Cardiology
Towards a Gene Therapy for Heart Regeneration
SEP 22, 2021
Towards a Gene Therapy for Heart Regeneration
For years, researchers at the Texas Heart Institute have been investigating the natural biochemical processes related to ...
Loading Comments...